Lutetium-177 DOTATATE: A Practical Review

Area of Science:

• Oncology
• Nuclear Medicine
• Endocrinology

Background:

• Neuroendocrine tumors (NETs) are diverse, with outcomes influenced by differentiation and grade.
• Advanced or metastatic NETs often resist standard treatments.
• Peptide receptor radionuclide therapy (PRRT) shows promise for refractory NETs.

Purpose of the Study:

• To evaluate the efficacy and safety of [¹⁷⁷Lu] Lu-DOTA-[Tyr³]-octreotate in patients with somatostatin receptor-positive gastroenteropancreatic NETs.
• To compare PRRT with standard therapy in a phase III clinical trial.

Main Methods:

• The NETTER-1 trial was a phase III study comparing [¹⁷⁷Lu] Lu-DOTA-[Tyr³]-octreotate plus octreotide versus octreotide alone.
• Participants had somatostatin receptor-positive, locally advanced or metastatic gastroenteropancreatic NETs.

Main Results:

• [¹⁷⁷Lu] Lu-DOTA-[Tyr³]-octreotate significantly improved disease-free survival compared to octreotide alone.
• The treatment demonstrated a favorable toxicity profile.
• This led to FDA approval for the therapy.

Conclusions:

• [¹⁷⁷Lu] Lu-DOTA-[Tyr³]-octreotate is an effective new treatment for advanced gastroenteropancreatic NETs.
• It expands the role of radiation therapy in NET management.
• Ongoing trials will further define its clinical utility.